Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over 12,000 men in Sweden.
A new study suggests the investigational Stockholm3 blood test may improve the early detection of aggressive prostate cancer compared with the standard PSA test.
A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...
NeoGenomics, Inc.(NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PTEN IHC CDx, the first immunohistochemistry (IHC) ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of ...
HealthDay on MSN
Calling low-risk prostate cancer something else might save more lives, researchers argue
Key Takeaways Renaming the lowest-grade prostate cancer to something other than cancer might save men’s livesThese GG1 cases ...
11don MSN
Should lowest-risk prostate 'cancer' still be called cancer? How changing the name could save lives
A growing number of prostate cancer experts argue that calling the lowest-risk prostate cancer "cancer" does more harm than ...
The Korean Urological Oncology Society (President Jeong Byeong-chang) held a press conference at the Korea Press Center on the 16th and announced the '2026 ...
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results